Get started
Author

Licui Jiang

Institution: PersonGen (China)
ORCID: 0009-0004-5996-7117
Observed ORCID: 0009-0004-5996-7117
OpenAlex ID: A5071935361
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
2016 · Fengtao You, Licui Jiang, et al. · Science China Life Sciences · 157
PDF
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
2019 · Fengtao You, Yinyan Wang, et al. · Europe PMC (PubMed Central) · 127
Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
2017 · Ying Chen, Fengtao You, et al. · Oncotarget · 53
PDF
MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
2021 · Xiaochen Zhai, Fengtao You, et al. · PubMed · 27
B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2024 · Licui Jiang, Fengtao You, et al. · Cancer Research · 25
Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia
2022 · Tingting Zhang, Tian Wang, et al. · Transplant Immunology · 20
PDF
CD7 protein plays a crucial role in T cell infiltration in tumors
2023 · Binjie Sheng, Kailu Zhang, et al. · Heliyon · 13
PDF
Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
2021 · Dan Chen, Fengtao You, et al. · PubMed · 11
Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
2026 · Chang Liu, Jiarui Li, et al. · Clinical Cancer Research · 6
Abstract 5255: A B7-H3-CAR-modified Vδ1 T cells showed potentanti-solid tumor potential
2024 · Licui Jiang, Changsong Qi, et al. · Cancer Research · 2
Data from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
2026 · Chang Liu, Jiarui Li, et al. · 1
Co-Expression of IL-2 Enhances the Efficacy of FLT3-CAR-γδT Cells in Acute Myeloid Leukemia
2026 · Xiaona Wang, Fengtao You, et al. · Cancers · 1
PDF
Figure S2 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Figure S9 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Figure S7 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Figure S1 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Figure S3 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Figure S4 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Supplementary Figure 1-8 from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
2026 · Chang Liu, Jiarui Li, et al.
Figure S6 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Figure S8 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Figure S5 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2026 · Licui Jiang, Fengtao You, et al.
Supplementary Table 1-5 from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
2026 · Chang Liu, Jiarui Li, et al.
Figure S2 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2024 · Licui Jiang, Fengtao You, et al.
Figure S5 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
2024 · Licui Jiang, Fengtao You, et al.
Works count: 34
Citation count: 443
H-index: 8
I10-index: 8
Year
Topic
Type